FMC stock at EUR 37.96, target sits 0.1 percent higher

Published on 10/12/2026 at 13:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Goldman Sachs cut its target to EUR 38.00 on September 30, 2026. FMC stock costs EUR 37.96 on October 12, 2026, plus 1.23 percent versus EUR 37.50.

Key points in brief

FMC stock was EUR 37.96 at Lang & Schwarz on October 12, 2026, up 1.23 percent versus the Xetra close of EUR 37.50.
The stock was 20.69 percent below its 52-week high of EUR 47.86.
Goldman Sachs cut its FMC target from EUR 39.00 to EUR 38.00 and retained a Neutral rating on September 30, 2026.
Fresenius Medical Care is scheduled to publish third-quarter 2026 results on November 3, 2026.
FMC trades at a P/E ratio of 11.42, versus 15.75 for DaVita and 22.12 for ResMed.

Trading-Monitore mit MDAX-Index und Healthcare-Sektorindex, Hände auf Tastatur im Vordergrund — Eine Finanz-Editorial-Aufnahme mit Trading-Monitoren, MDAX-Kursdaten und einem Healthcare-Sektorindex – passend zum Börsenkontext der Fresenius Medical Care AG (ISIN DE0005785802) als MDAX-notiertes Medizintechnikunternehmen, Illustration mit AI erstellt.

FMC stock was trading at EUR 37.96 at Lang & Schwarz on October 12, 2026 at 1:00 p.m. CEST, up 1.23 percent versus the Xetra close of October 9, 2026 at EUR 37.50. The price was EUR 0.04 below the EUR 38.00 target that Goldman Sachs set in a note dated September 30, 2026, while retaining its Neutral rating, as FinanzNachrichten reports.

Trading range remains wide

The current euro quote stood 20.69 percent below the 52-week high of EUR 47.86 and EUR 3.39 above the 52-week low of EUR 34.57. Both range points and the current quote are dated October 12, 2026, giving the stock a measurable position inside its annual band.

The Lang & Schwarz bid was EUR 37.85 and the ask EUR 38.07 at 1:00 p.m. CEST. Trading volume on Xetra was 167,311 shares against an average volume of 823,907 shares in the quote data dated October 12, 2026.

Valuation before November results

Fresenius Medical Care had a market capitalization of EUR 10.1 billion and a P/E ratio of 11.42 on October 12, 2026. The company is scheduled to publish its third-quarter 2026 results on November 3, 2026, according to Fresenius Medical Care.

The official stock information identifies Fresenius Medical Care as listed on Xetra and the Frankfurt Stock Exchange, with ticker FME and ISIN DE0005785802. It also identifies a New York Stock Exchange American Depositary Receipt under ticker FMS, but that listing is separate from the euro reference price used here, as Fresenius Medical Care states.

Comparison with peers

FMC: plus 1.23 percent, P/E 11.42, market capitalization EUR 10.1 billion
DaVita (NYSE, USD): plus 1.26 percent, P/E 15.75, market capitalization USD 11.5 billion
ResMed (NYSE, USD): plus 1.46 percent, P/E 22.12, market capitalization USD 33.4 billion

The DaVita and ResMed figures reflect their latest quoted US session dated October 9, 2026. Their higher P/E ratios place FMC at the lower end of this three-company comparison, while the different currencies and listing venues prevent a direct share-price comparison.

FMC stock before the results date

The November 3 reporting date is the next scheduled company event. Until then, the key market markers are the EUR 37.50 Xetra close, the EUR 38.00 analyst target and the 20.69 percent gap to the annual high.

FMC was trading at EUR 37.96 at Lang & Schwarz on October 12, 2026 at 1:00 p.m. CEST, plus 1.23 percent versus the Xetra close of October 9, 2026 at EUR 37.50. The further course of trading is shown by the continuously updated real-time quote of FMC stock.